EXT1 Gene Chondrosarcoma familial Genetic Test
At DNA Labs UAE, we offer the EXT1 Gene Chondrosarcoma familial Genetic Test. This test is designed to analyze the DNA sequence of the EXT1 gene in individuals with a family history of hereditary multiple exostoses (HME) or chondrosarcoma. By identifying genetic variations in the EXT1 gene, we can help assess the risk of developing these conditions and provide appropriate management and surveillance options.
Test Details
The EXT1 gene is associated with hereditary multiple exostoses, a condition characterized by the growth of multiple benign bone tumors called osteochondromas. In some individuals with HME, these osteochondromas can develop into chondrosarcoma, a rare type of cancer. Our familial NGS genetic testing utilizes Next-Generation Sequencing technology to analyze the EXT1 gene and identify any mutations or variations that may increase the risk of developing these conditions.
Test Components and Price
The EXT1 Gene Chondrosarcoma familial Genetic Test is priced at 4400.0 AED. The test can be performed using a blood sample, extracted DNA, or one drop of blood on an FTA card.
Report Delivery and Method
After the sample is received, the report will be delivered within 3 to 4 weeks. The test utilizes NGS Technology for analysis.
Test Type and Doctor
The EXT1 Gene Chondrosarcoma familial Genetic Test falls under the category of Osteology Dermatology Immunology Disorders. This test is typically recommended by dermatologists. The test is conducted in our Genetics department.
Pre Test Information
Prior to the test, it is important to provide the clinical history of the patient who is undergoing the EXT1 Gene Chondrosarcoma familial NGS Genetic DNA Test. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by EXT1 Gene Chondrosarcoma familial NGS Genetic DNA Test.
Implications and Counseling
It is essential to note that a positive genetic test result does not guarantee the development of HME or chondrosarcoma, as other factors may also contribute to these conditions. Similarly, a negative test result does not rule out the possibility of developing HME or chondrosarcoma, as there may be other genes or factors involved that are not tested for. Therefore, genetic counseling is highly recommended for individuals considering familial NGS genetic testing. This counseling session will help understand the potential implications of the test results and discuss appropriate management and surveillance options.
| Test Name | EXT1 Gene Chondrosarcoma familial Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Osteology Dermatology Immunology Disorders |
| Doctor | Dermatologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for EXT1 Gene Chondrosarcoma, familial NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with EXT1 Gene Chondrosarcoma, familial NGS Genetic DNA Test gene EXT1 |
| Test Details |
The EXT1 gene is associated with a condition called hereditary multiple exostoses (HME), which is characterized by the growth of multiple benign bone tumors called osteochondromas. Chondrosarcoma is a rare type of cancer that can develop within these osteochondromas in some individuals with HME. Familial NGS genetic testing refers to Next-Generation Sequencing technology used to analyze the DNA sequence of the EXT1 gene in individuals with a family history of HME or chondrosarcoma. This test can identify mutations or variations in the EXT1 gene that may be associated with an increased risk of developing these conditions. By identifying these genetic variations, individuals at risk can undergo regular surveillance and monitoring to detect any potential development of osteochondromas or chondrosarcomas at an early stage. Early detection can lead to better treatment outcomes and potentially prevent the progression of the disease. It is important to note that a positive genetic test result does not guarantee the development of HME or chondrosarcoma, as other factors may also contribute to the development of these conditions. Additionally, a negative test result does not completely rule out the possibility of developing HME or chondrosarcoma, as there may be other genes or factors involved that are not tested for. Genetic counseling is recommended for individuals considering familial NGS genetic testing to understand the potential implications of the test results and to discuss appropriate management and surveillance options. |
